Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Mario Enrico Canonico

Concepts (189)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Peripheral Arterial Disease
10
2026
507
3.160
Why?
Platelet Aggregation Inhibitors
18
2026
499
2.810
Why?
Acute Coronary Syndrome
10
2026
299
2.300
Why?
Heart Failure
12
2026
2329
2.290
Why?
Mineralocorticoid Receptor Antagonists
3
2026
69
1.960
Why?
Stroke Volume
9
2026
652
1.930
Why?
Percutaneous Coronary Intervention
12
2026
550
1.840
Why?
Rivaroxaban
4
2026
270
1.840
Why?
Aspirin
6
2026
405
1.790
Why?
Factor Xa Inhibitors
3
2026
195
1.720
Why?
Fibrinolytic Agents
6
2025
303
1.670
Why?
Lower Extremity
5
2026
453
1.250
Why?
Bumetanide
2
2026
6
1.210
Why?
ST Elevation Myocardial Infarction
3
2026
65
1.020
Why?
Spironolactone
2
2026
40
1.000
Why?
Edema
1
2026
131
0.910
Why?
Vascular Surgical Procedures
2
2026
352
0.890
Why?
Liver Diseases
1
2026
304
0.770
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
2
2026
449
0.750
Why?
Kidney Diseases
1
2026
428
0.720
Why?
Delivery of Health Care, Integrated
1
2025
305
0.700
Why?
Thrombosis
2
2024
398
0.680
Why?
Anticholesteremic Agents
1
2023
156
0.680
Why?
Hyperglycemia
1
2025
384
0.670
Why?
Diabetes Mellitus, Type 2
3
2026
2623
0.670
Why?
Endovascular Procedures
1
2026
390
0.650
Why?
Purinergic P2Y Receptor Antagonists
8
2026
71
0.650
Why?
Hypertension
6
2026
1272
0.640
Why?
Adenosine Monophosphate
4
2026
87
0.630
Why?
Renal Insufficiency, Chronic
2
2025
640
0.600
Why?
Coronavirus
1
2020
47
0.600
Why?
Venous Thrombosis
1
2022
199
0.590
Why?
Blood Platelets
3
2024
382
0.590
Why?
Mobile Applications
1
2022
196
0.590
Why?
Hypoglycemic Agents
3
2026
1412
0.580
Why?
Pneumonia, Viral
2
2020
387
0.540
Why?
Coronavirus Infections
2
2020
379
0.540
Why?
Sex Characteristics
2
2025
801
0.540
Why?
Humans
55
2026
146342
0.540
Why?
Randomized Controlled Trials as Topic
7
2026
1763
0.520
Why?
Venous Thromboembolism
1
2022
332
0.510
Why?
Precision Medicine
1
2021
462
0.480
Why?
Hemorrhage
4
2026
825
0.480
Why?
Drug Therapy, Combination
5
2026
1036
0.470
Why?
Platelet Aggregation
4
2026
99
0.460
Why?
Blood Glucose
1
2025
2360
0.430
Why?
Treatment Outcome
15
2026
11821
0.420
Why?
Neoplasms
4
2024
2954
0.410
Why?
International Classification of Diseases
2
2025
142
0.410
Why?
Diabetes Mellitus
1
2022
1101
0.400
Why?
Ventricular Function, Left
5
2026
541
0.400
Why?
Pragmatic Clinical Trials as Topic
2
2025
135
0.390
Why?
Coronary Artery Disease
4
2025
751
0.380
Why?
Aged
18
2026
26432
0.380
Why?
Pandemics
2
2020
1707
0.360
Why?
Multicenter Studies as Topic
2
2025
417
0.360
Why?
Double-Blind Method
3
2026
2070
0.350
Why?
Postoperative Complications
1
2024
3034
0.340
Why?
Middle Aged
17
2026
36619
0.340
Why?
Aged, 80 and over
6
2026
8391
0.330
Why?
Antihypertensive Agents
2
2026
519
0.320
Why?
Blood Pressure
4
2026
1765
0.310
Why?
Nasal Sprays
2
2026
7
0.300
Why?
Male
24
2026
73396
0.300
Why?
Administration, Intranasal
2
2026
95
0.300
Why?
Prevalence
4
2025
2861
0.280
Why?
Anticoagulants
4
2022
746
0.280
Why?
Natriuretic Peptide, Brain
2
2026
110
0.270
Why?
Female
20
2026
79499
0.260
Why?
Ventricular Dysfunction, Left
2
2021
391
0.250
Why?
Betacoronavirus
2
2020
288
0.250
Why?
Risk Factors
7
2026
10921
0.250
Why?
Dicarboxylic Acids
1
2026
12
0.240
Why?
Incretins
1
2026
21
0.240
Why?
Aminobutyrates
1
2026
31
0.230
Why?
Tetrazoles
1
2026
50
0.230
Why?
Chagas Cardiomyopathy
1
2026
27
0.230
Why?
Immunoglobulin Fc Fragments
1
2026
41
0.230
Why?
Limb Salvage
1
2026
74
0.230
Why?
Adenosine
2
2024
256
0.220
Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2025
17
0.220
Why?
Diuretics
1
2025
66
0.220
Why?
Atrial Fibrillation
2
2021
560
0.220
Why?
Coronary Angiography
4
2021
325
0.210
Why?
Peptide Fragments
2
2026
693
0.210
Why?
Hospitalization
2
2025
2475
0.210
Why?
Glucagon-Like Peptides
1
2026
76
0.210
Why?
Morphine Derivatives
1
2023
19
0.200
Why?
Tablets
1
2023
41
0.200
Why?
Ventricular Remodeling
1
2026
283
0.200
Why?
Subtilisin
1
2023
4
0.200
Why?
Secondary Prevention
1
2025
248
0.200
Why?
Cardiology
2
2025
363
0.190
Why?
Proprotein Convertases
1
2023
16
0.190
Why?
Recombinant Fusion Proteins
1
2026
663
0.190
Why?
Fatty Acids
1
2026
460
0.190
Why?
Proprotein Convertase 9
1
2023
88
0.190
Why?
Comorbidity
2
2025
1665
0.180
Why?
Atrial Remodeling
1
2022
10
0.180
Why?
Clinical Trials, Phase III as Topic
1
2022
116
0.180
Why?
Echocardiography
5
2024
645
0.170
Why?
Bundle-Branch Block
1
2021
37
0.170
Why?
Glucosephosphate Dehydrogenase Deficiency
1
2021
34
0.170
Why?
Cholesterol, LDL
1
2023
363
0.170
Why?
Cardiotoxicity
1
2021
35
0.170
Why?
Atherosclerosis
1
2025
410
0.170
Why?
Frailty
1
2024
208
0.160
Why?
Drug Compounding
1
2021
106
0.160
Why?
Coronary Stenosis
1
2020
40
0.160
Why?
Coronary Occlusion
1
2020
20
0.160
Why?
Radial Artery
2
2021
74
0.150
Why?
Drug-Eluting Stents
1
2020
88
0.150
Why?
Myocarditis
1
2021
103
0.150
Why?
Angioplasty, Balloon, Coronary
1
2021
156
0.150
Why?
Smoking Cessation
1
2024
442
0.150
Why?
Ambulatory Care
1
2025
628
0.150
Why?
Shock, Cardiogenic
1
2020
65
0.150
Why?
Angioplasty, Balloon
1
2021
92
0.150
Why?
Cardiopulmonary Resuscitation
1
2023
334
0.150
Why?
Italy
3
2025
118
0.140
Why?
Heart Arrest
1
2023
411
0.140
Why?
Chronic Disease
1
2025
1827
0.140
Why?
Cross-Sectional Studies
3
2025
5899
0.140
Why?
Hepatitis C, Chronic
1
2020
150
0.140
Why?
United States
3
2025
16136
0.130
Why?
Pulmonary Embolism
1
2020
246
0.130
Why?
Students, Medical
1
2023
383
0.130
Why?
Time Factors
2
2026
7109
0.130
Why?
Registries
5
2026
2400
0.130
Why?
Cardiomyopathies
1
2021
340
0.130
Why?
Biomarkers
2
2025
4340
0.120
Why?
Retrospective Studies
6
2025
17438
0.120
Why?
Telemedicine
1
2025
966
0.110
Why?
Antibodies, Monoclonal
1
2023
1512
0.110
Why?
Femoral Artery
1
2016
183
0.110
Why?
Colorado
1
2025
4595
0.110
Why?
Heart Ventricles
1
2020
762
0.110
Why?
Cross-Over Studies
2
2025
615
0.090
Why?
Antineoplastic Agents
1
2024
2219
0.090
Why?
Obesity
1
2026
3131
0.090
Why?
Cardiac Catheterization
1
2016
571
0.090
Why?
Administration, Oral
2
2021
872
0.070
Why?
Cardiovascular Diseases
1
2020
2219
0.070
Why?
Prospective Studies
3
2026
8123
0.070
Why?
Prognosis
3
2021
4351
0.070
Why?
Animals
2
2026
38107
0.060
Why?
Valsartan
1
2026
33
0.060
Why?
Biphenyl Compounds
1
2026
67
0.060
Why?
Naphthyridines
1
2025
20
0.060
Why?
Angiotensin Receptor Antagonists
1
2026
115
0.060
Why?
Receptors, Purinergic P2Y12
1
2024
6
0.050
Why?
Biological Availability
1
2025
146
0.050
Why?
Platelet Function Tests
1
2024
37
0.050
Why?
Drug Combinations
1
2026
400
0.050
Why?
Hypolipidemic Agents
1
2025
89
0.050
Why?
Adult
3
2022
41087
0.050
Why?
Risk Assessment
2
2025
3712
0.050
Why?
Recurrence
1
2026
1133
0.050
Why?
Drug Administration Schedule
1
2024
790
0.050
Why?
Prasugrel Hydrochloride
1
2022
22
0.040
Why?
Equivalence Trials as Topic
1
2022
35
0.040
Why?
Emergencies
1
2023
177
0.040
Why?
Gadolinium
1
2021
78
0.040
Why?
Vitamin K
1
2021
46
0.040
Why?
Heart Atria
1
2022
139
0.040
Why?
Glucosephosphate Dehydrogenase
1
2021
70
0.040
Why?
Exercise Therapy
1
2025
488
0.040
Why?
Disease Management
1
2024
651
0.040
Why?
Sex Factors
1
2025
2107
0.040
Why?
Hypertrophy, Left Ventricular
1
2020
124
0.040
Why?
Hepacivirus
1
2020
237
0.040
Why?
Coronary Vessels
1
2020
245
0.030
Why?
Contrast Media
1
2021
493
0.030
Why?
Acute Disease
1
2021
1038
0.030
Why?
Ventricular Dysfunction, Right
1
2020
248
0.030
Why?
Age Factors
1
2024
3347
0.030
Why?
Dose-Response Relationship, Drug
1
2021
2022
0.030
Why?
Predictive Value of Tests
1
2022
2113
0.030
Why?
Logistic Models
1
2021
2126
0.030
Why?
Stents
1
2020
554
0.030
Why?
Severity of Illness Index
1
2021
2921
0.020
Why?
Incidence
1
2020
2936
0.020
Why?
Cost-Benefit Analysis
1
2016
640
0.020
Why?
Body Mass Index
1
2022
2458
0.020
Why?
Quality of Life
1
2025
3200
0.020
Why?
Patient Safety
1
2016
352
0.020
Why?
Cohort Studies
1
2021
6077
0.020
Why?
Length of Stay
1
2016
1358
0.020
Why?
Hypertension, Pulmonary
1
2020
1957
0.020
Why?
Canonico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)